Theranos scandal whistleblower warns AI boom is a perfect opportunity to mislead investors under a veil of secrecy

When Tyler Schultz exposed the fake blood-testing devices at Theranos, he had witnessed, in his first post-graduation role, a valuation that reached ten billion dollars for a technology that never worked. The company, which marketed its devices to Walgreens stores and delivered misleading results to real patients, had secretly relied on third-party equipment for most of its tests instead of its own machines. Today, a decade after that episode, Schultz believes the current AI boom presents an ideal opportunity to repeat the deception on a unprecedented scale, in an environment where capital streams with trillion-dollar valuations toward companies that have yet to generate operating profits. The warning Schultz issued in his interview with the San Francisco Standard, relayed by TechCrunch, revives the technical-audit file in Silicon Valley, a signal we find highly significant for anyone tracking funding flows, cautioning against forgetting the harshest lesson in venture-capital history.

The pivotal problem in today’s AI landscape, as defined by Schultz, lies in the extreme difficulty of due-diligence testing.Distinguishing a genuine, unique technological innovation from a mere superficial veneer of a model like ChatGPT has become a complex challenge for major investors.This inability to differentiate gives claimants of loose assertions an ideal cover, just as Elizabeth Holmes refrained from sharing scientific evidence under the pretext of protecting trade secrets, a tactic that drove away major venture-capital funds but attracted wealthy families such as the DeVos and Walton families, as well as prominent figures like former U.S. Secretary of State and Treasury George Schultz and Tyler himself.

Schultz notes that the model of a half-hour coffee meeting followed by a $100,000 transfer has become obsolete, after Holmes copied it and escalated it to $100 million through what she describes as the largest angel-funding round in history. Yet the danger does not lie in the raw number but in the immense power granted to a founder simply by placing that liquidity in their hands without demanding tangible engineering proof. The paradox deepens while Holmes serves a federal prison sentence exceeding eleven years, as the documentary *You Can See Everything* by directors Nathan Feldr and Lance Oppenheim revealed her efforts with partner Billy Evans to launch a new diagnostics company called Heimanthos and raise about $20 million for a project insiders describe as a second incarnation of Theranos.

This intelligence warning places decision-makers in the Gulf, Egypt and the Levant before a direct professional imperative. With Gulf liquidity, family offices and investment funds flowing toward digital-transformation deals and generative-model solutions, the risk of being misled by glossy interfaces and pre-packaged demos is growing. Purchasing an AI platform or investing in a startup based on appearances of credibility without conducting an independent code audit of the model’s architecture and inference scripts threatens to waste massive budgets on intermediary software that holds no proprietary intellectual property. The practical decision required of regional tech leaders and banks mandates the technical reproducibility of results and a refusal to invoke trade-secret claims to conceal model mechanisms from engineering review teams.

Engineering credibility is not built on the prestige of sponsoring names or on massive valuation figures, but on demonstrating the system’s competence in real-world operation.Protecting investments in the region requires replacing impulsive enthusiasm with stringent, investigative testing standards, recognizing that lax technical due-diligence does not develop a sector but reproduces costly illusory promises under new software banners.